IL248169A0 - il-15 group conjugates and polymer - Google Patents

il-15 group conjugates and polymer

Info

Publication number
IL248169A0
IL248169A0 IL248169A IL24816916A IL248169A0 IL 248169 A0 IL248169 A0 IL 248169A0 IL 248169 A IL248169 A IL 248169A IL 24816916 A IL24816916 A IL 24816916A IL 248169 A0 IL248169 A0 IL 248169A0
Authority
IL
Israel
Prior art keywords
conjugates
moiety
polymer
Prior art date
Application number
IL248169A
Other languages
English (en)
Hebrew (he)
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of IL248169A0 publication Critical patent/IL248169A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2086IL-13 to IL-16
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48Polymers modified by chemical after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL248169A 2014-04-03 2016-10-02 il-15 group conjugates and polymer IL248169A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461974914P 2014-04-03 2014-04-03
PCT/US2015/023871 WO2015153753A2 (en) 2014-04-03 2015-04-01 Conjugates of an il-15 moiety and a polymer

Publications (1)

Publication Number Publication Date
IL248169A0 true IL248169A0 (en) 2016-11-30

Family

ID=54241432

Family Applications (1)

Application Number Title Priority Date Filing Date
IL248169A IL248169A0 (en) 2014-04-03 2016-10-02 il-15 group conjugates and polymer

Country Status (12)

Country Link
US (1) US20170035898A1 (cg-RX-API-DMAC7.html)
EP (2) EP3139947B8 (cg-RX-API-DMAC7.html)
JP (2) JP6728055B2 (cg-RX-API-DMAC7.html)
KR (1) KR102432169B1 (cg-RX-API-DMAC7.html)
CN (1) CN106456716A (cg-RX-API-DMAC7.html)
AU (3) AU2015240806B2 (cg-RX-API-DMAC7.html)
CA (1) CA2942571C (cg-RX-API-DMAC7.html)
ES (1) ES2876433T3 (cg-RX-API-DMAC7.html)
IL (1) IL248169A0 (cg-RX-API-DMAC7.html)
MA (1) MA39711A (cg-RX-API-DMAC7.html)
MX (2) MX388865B (cg-RX-API-DMAC7.html)
WO (1) WO2015153753A2 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014254019B2 (en) 2013-04-18 2018-09-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
AU2014281828B2 (en) 2013-06-17 2019-05-09 Armo Biosciences, Inc. Method for assessing protein identity and stability
HK1226308A1 (zh) 2013-08-30 2017-09-29 Armo Biosciences, Inc. 使用白细胞介素-10治疗疾病和病症的方法
BR112016010166A2 (pt) 2013-11-11 2017-12-05 Armo Biosciences Inc métodos para usar interleucina-10 para tratar doenças e distúrbios
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
CA2963989A1 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
CN108025040A (zh) 2015-08-25 2018-05-11 阿尔莫生物科技股份有限公司 使用白介素-10治疗疾病和病症的方法
WO2017062832A1 (en) 2015-10-08 2017-04-13 Nektar Therapeutics Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
BR112018012262A2 (pt) * 2015-12-21 2018-12-04 Armo Biosciences Inc composições de interleucina-15 e seus usos
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
WO2018213341A1 (en) * 2017-05-15 2018-11-22 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
BR112020017016A2 (pt) 2018-02-26 2020-12-29 Synthorx, Inc. Conjugados da il-15 e usos dos mesmos
US20210393742A1 (en) * 2018-11-09 2021-12-23 Nektar Therapeutics Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent
WO2020219943A1 (en) * 2019-04-26 2020-10-29 Prolynx Llc Slow-release cytokine conjugates
US11248025B2 (en) 2019-06-03 2022-02-15 Medikine, Inc. IL-2alpha receptor subunit binding compounds
TW202122401A (zh) * 2019-08-23 2021-06-16 美商欣爍克斯公司 新穎之il-15接合物及其用途
US20240269293A1 (en) * 2021-03-29 2024-08-15 Beijing Xuanyi Pharmasciences Co., Ltd. Protein-macromolecule conjugates and methods of use thereof
WO2022268991A1 (en) 2021-06-23 2022-12-29 Cytune Pharma Interleukin 15 variants
EP4370536A2 (en) * 2021-07-12 2024-05-22 Nektar Therapeutics Polymer engineered forms of interferon-gamma and methods of use
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2025101551A1 (en) * 2023-11-06 2025-05-15 Regents Of The University Of Minnesota Prostate-specific membrane antigen (psma)-binding peptides and method of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
AU1096595A (en) * 1993-11-12 1995-05-29 Gilead Sciences, Inc. Thrombin mutants
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
WO1995027722A1 (en) 1994-04-06 1995-10-19 Immunex Corporation Interleukin-15
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US7008624B1 (en) * 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
US5795966A (en) 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
EP1061954B1 (en) 1998-03-12 2004-06-09 Nektar Therapeutics Al, Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
US7432330B2 (en) * 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
AU2004204136B2 (en) 2003-01-06 2008-10-09 Nektar Therapeutics Thiol-selective water-soluble polmer derivatives
WO2005030196A2 (en) * 2003-09-25 2005-04-07 Zymogenetics, Inc. Methods of treating autoimmune diseases using il-21
TW200613552A (en) * 2004-08-11 2006-05-01 Hoffmann La Roche Mutant interleukin-15 polypeptides
AU2005335217A1 (en) 2004-10-05 2007-02-15 Ochsner Clinic Foundation Enhancement of B cell proliferation by IL-15
US20060257361A1 (en) * 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
JP5081820B2 (ja) 2005-06-16 2012-11-28 ネクター セラピューティックス 分解性結合を有する複合体と該複合体の調製に有益なポリマー試薬
KR101508621B1 (ko) 2007-02-28 2015-04-07 세리나 쎄라퓨틱스, 인코포레이티드 활성화된 폴리옥사졸린 및 이를 포함하는 조성물
EP2350658A2 (en) * 2008-10-21 2011-08-03 Baxter International Inc. Methods for determining active ingredients in pro-drug peg protein conjugates with releasable peg reagents (in vitro de-pegylation)
KR102269494B1 (ko) * 2010-07-30 2021-06-25 박스알타 인코퍼레이티드 옥심 결합용 친핵성 촉매
MX358399B (es) * 2010-11-12 2018-08-16 Nektar Therapeutics Conjugados de un resto de interleucina-2 y un polímero.
CN102145178B (zh) * 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
WO2013020079A2 (en) * 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer

Also Published As

Publication number Publication date
EP3139947A2 (en) 2017-03-15
AU2019283778A1 (en) 2020-01-16
EP3139947B1 (en) 2021-05-26
MX2021015492A (es) 2022-02-22
US20170035898A1 (en) 2017-02-09
EP3139947B8 (en) 2021-06-30
JP2017511322A (ja) 2017-04-20
JP2020114875A (ja) 2020-07-30
AU2015240806A1 (en) 2016-10-13
KR102432169B1 (ko) 2022-08-11
KR20170005793A (ko) 2017-01-16
MX2016012908A (es) 2017-01-11
JP6728055B2 (ja) 2020-07-22
EP3139947A4 (en) 2018-01-17
CA2942571A1 (en) 2015-10-08
AU2015240806B2 (en) 2019-09-19
CA2942571C (en) 2023-09-19
WO2015153753A2 (en) 2015-10-08
MA39711A (fr) 2015-10-08
MX388865B (es) 2025-03-20
EP3919071A1 (en) 2021-12-08
ES2876433T3 (es) 2021-11-12
AU2021258008A1 (en) 2021-11-25
CN106456716A (zh) 2017-02-22
WO2015153753A3 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
IL248169A0 (en) il-15 group conjugates and polymer
IL289802A (en) Biomolecular couplings
GB2513048B (en) Device proximity
ZA201704297B (en) Pyrrolobenzodiazepine-antibody conjugates
PT3119885T (pt) Conjugados anticorpo-fynomer
EP3183262A4 (en) Novel glycan conjugates and use thereof
GB2525767B (en) Speaker device
EP3207128A4 (en) Butyrylcholinesterase zwitterionic polymer conjugates
EP3094985A4 (en) Determination of a location of a device
EP3285799A4 (en) Conjugates of an il-7 moiety and an polymer
EP3158628A4 (en) Electromagnetic device
EP3192439A4 (en) Bioinformation measuring device
IL248443B (en) A device that can be integrated into a skeletal bone
EP3073763A4 (en) Speaker device
GB201402998D0 (en) Amplifier device
EP3214854A4 (en) Speaker device
EP3166335A4 (en) Speaker device
GB201418068D0 (en) Polymer
GB201409933D0 (en) Novel device
IL246349A0 (en) factor vii conjugates
SG11201704325QA (en) Micro-cavity-based force sensor
EP3110513A4 (en) Willow workout device
GB201420946D0 (en) Flexible device incorporating microperforators
EP3214853A4 (en) Speaker device
GB201402404D0 (en) Polymer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed